Recent developments for Pseudomonas vaccines

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

“…Trials have not found investigational vaccines to be efficacious. [462][463][464] Vaccinations for family members and close contacts of people with CF. Vaccination of family members and close contacts of people with CF can help to protect people with CF from vaccine-preventable illnesses.…”

Mucosal and systemic antibody responses to potentialPseudomonas aeruginosavaccine protein antigens in young children with cystic fibrosis following colonization and infection

“…The order of the antigen specific IgG membrane proteins (Oprs), F (OprF) and I (OprI), are lead vaccine candidate antigens. [15][16][17] Preventing P. aeruginosa infection by vaccinating CF patients has been a goal for many years, but despite numerous animal studies and several human trials, an efficacious vaccine for P. aeruginosa remains elusive. [18][19][20] Several P. aeruginosa antigens invoke the characteristic rise in antibody titers as the disease state progresses and can be detected in the sera, sputa, saliva, tears and bronchoalveolar lavage (BAL) fluid from CF patients.…”

Synthesis, Characterization, and Immunological Properties of LPS-Based Vaccines Composed of O-Polysaccharides Conjugated with Recombinant Exoprotein A from <i>Pseudomonas aeruginosa</i>

“…Pseudomonas aeruginosa is a major cause of morbidity and mortality for immunocompromised patients, especially in individuals with cystic fibrosis, severe burns, or cancer [1] [2]. In these patients, P. aeruginosa is one of the most dangerous nosocomial pathogens, due to its production of several virulence factors such as exotoxin A, exoenzyme S, elastase, alginate and lipopolysaccharide (LPS) [3] [4]; emergence of multidrug resistant strains [5]; and absence of an efficient protective vaccine [2].…”